Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Melanoma | 24 | 2018 | 331 | 5.550 |
Why?
|
Skin Neoplasms | 26 | 2025 | 414 | 5.080 |
Why?
|
Biomarkers, Tumor | 10 | 2019 | 503 | 1.780 |
Why?
|
Microphthalmia-Associated Transcription Factor | 3 | 2016 | 13 | 1.460 |
Why?
|
Serpins | 3 | 2016 | 18 | 1.460 |
Why?
|
Nerve Growth Factors | 3 | 2016 | 27 | 1.460 |
Why?
|
Eye Proteins | 3 | 2016 | 74 | 1.420 |
Why?
|
MicroRNAs | 5 | 2017 | 680 | 1.400 |
Why?
|
MART-1 Antigen | 3 | 2018 | 8 | 1.130 |
Why?
|
SOXE Transcription Factors | 2 | 2018 | 6 | 0.930 |
Why?
|
Hemangioma | 3 | 2011 | 28 | 0.920 |
Why?
|
Lymphangiogenesis | 4 | 2013 | 14 | 0.890 |
Why?
|
Lymphatic Metastasis | 4 | 2016 | 82 | 0.880 |
Why?
|
Gene Expression Regulation, Neoplastic | 3 | 2015 | 521 | 0.810 |
Why?
|
Melanocytes | 4 | 2018 | 80 | 0.770 |
Why?
|
Nevus, Pigmented | 3 | 2018 | 19 | 0.760 |
Why?
|
Hemangioendothelioma | 3 | 2010 | 5 | 0.710 |
Why?
|
Homeodomain Proteins | 4 | 2014 | 267 | 0.680 |
Why?
|
Tumor Suppressor Proteins | 3 | 2011 | 198 | 0.670 |
Why?
|
Melanoma-Specific Antigens | 2 | 2016 | 5 | 0.630 |
Why?
|
Muir-Torre Syndrome | 1 | 2019 | 1 | 0.620 |
Why?
|
Immunohistochemistry | 9 | 2019 | 890 | 0.610 |
Why?
|
Keratosis, Actinic | 1 | 2018 | 4 | 0.580 |
Why?
|
Skin Diseases | 2 | 2016 | 83 | 0.560 |
Why?
|
Up-Regulation | 3 | 2011 | 375 | 0.550 |
Why?
|
TRPM Cation Channels | 1 | 2016 | 15 | 0.520 |
Why?
|
Vascular Endothelial Growth Factor C | 3 | 2013 | 20 | 0.520 |
Why?
|
Humans | 46 | 2025 | 62865 | 0.480 |
Why?
|
Cutis Laxa | 1 | 2014 | 7 | 0.470 |
Why?
|
Aged | 17 | 2025 | 14268 | 0.460 |
Why?
|
Neovascularization, Pathologic | 3 | 2004 | 140 | 0.460 |
Why?
|
Sarcoidosis | 1 | 2015 | 34 | 0.460 |
Why?
|
Psoriasis | 1 | 2015 | 55 | 0.460 |
Why?
|
Vulvar Neoplasms | 2 | 2011 | 11 | 0.460 |
Why?
|
Female | 29 | 2019 | 32566 | 0.440 |
Why?
|
Amyloidosis | 1 | 2014 | 63 | 0.440 |
Why?
|
Nail Diseases | 1 | 2014 | 49 | 0.430 |
Why?
|
Male | 24 | 2025 | 29552 | 0.420 |
Why?
|
Precancerous Conditions | 2 | 2011 | 70 | 0.420 |
Why?
|
Aged, 80 and over | 8 | 2018 | 5408 | 0.410 |
Why?
|
Epidermal Growth Factor | 1 | 2013 | 47 | 0.400 |
Why?
|
Disease Models, Animal | 4 | 2016 | 2179 | 0.390 |
Why?
|
Middle Aged | 14 | 2018 | 17391 | 0.390 |
Why?
|
Gene Expression Regulation | 4 | 2016 | 1614 | 0.380 |
Why?
|
Carcinoma, Verrucous | 1 | 2011 | 3 | 0.370 |
Why?
|
Sentinel Lymph Node Biopsy | 2 | 2008 | 40 | 0.360 |
Why?
|
Ribonuclease III | 1 | 2011 | 88 | 0.350 |
Why?
|
Carcinoma in Situ | 1 | 2011 | 35 | 0.350 |
Why?
|
Sensitivity and Specificity | 5 | 2018 | 1140 | 0.350 |
Why?
|
Soft Tissue Neoplasms | 1 | 2010 | 31 | 0.340 |
Why?
|
Neoplasm Metastasis | 5 | 2014 | 200 | 0.330 |
Why?
|
Cicatrix | 1 | 2010 | 61 | 0.330 |
Why?
|
Lymph Nodes | 2 | 2008 | 222 | 0.330 |
Why?
|
Transcriptome | 1 | 2013 | 385 | 0.330 |
Why?
|
Tissue Fixation | 1 | 2009 | 21 | 0.320 |
Why?
|
Paraffin Embedding | 1 | 2009 | 17 | 0.320 |
Why?
|
Formaldehyde | 1 | 2009 | 34 | 0.320 |
Why?
|
Membrane Glycoproteins | 6 | 2011 | 669 | 0.320 |
Why?
|
Multiple Myeloma | 1 | 2014 | 348 | 0.320 |
Why?
|
Oxidoreductases | 3 | 2001 | 64 | 0.320 |
Why?
|
Child | 8 | 2018 | 4477 | 0.310 |
Why?
|
Neoplasm Invasiveness | 4 | 2014 | 272 | 0.300 |
Why?
|
Microbodies | 3 | 1996 | 4 | 0.300 |
Why?
|
Sarcoma, Kaposi | 1 | 2008 | 17 | 0.290 |
Why?
|
Adult | 13 | 2018 | 16672 | 0.290 |
Why?
|
Diagnosis, Differential | 6 | 2015 | 964 | 0.280 |
Why?
|
Animals | 21 | 2017 | 20620 | 0.270 |
Why?
|
DNA Mutational Analysis | 2 | 2019 | 196 | 0.270 |
Why?
|
Skin | 4 | 2017 | 377 | 0.270 |
Why?
|
Cell Line, Tumor | 6 | 2014 | 1455 | 0.260 |
Why?
|
Neoplasms | 2 | 2009 | 1350 | 0.250 |
Why?
|
Lymphatic System | 2 | 2005 | 19 | 0.240 |
Why?
|
Hair | 2 | 2017 | 83 | 0.240 |
Why?
|
Child, Preschool | 6 | 2011 | 1962 | 0.240 |
Why?
|
Mice | 15 | 2016 | 10819 | 0.230 |
Why?
|
Vascular Neoplasms | 1 | 2004 | 17 | 0.230 |
Why?
|
Phenotype | 3 | 2019 | 1197 | 0.220 |
Why?
|
Hematologic Neoplasms | 1 | 2025 | 49 | 0.220 |
Why?
|
Polymerase Chain Reaction | 4 | 2014 | 516 | 0.220 |
Why?
|
Cell Movement | 4 | 2014 | 445 | 0.220 |
Why?
|
Dendritic Cells | 3 | 2025 | 523 | 0.220 |
Why?
|
In Situ Hybridization | 3 | 2016 | 218 | 0.220 |
Why?
|
Young Adult | 5 | 2018 | 4655 | 0.210 |
Why?
|
Vesicular Transport Proteins | 4 | 2010 | 113 | 0.200 |
Why?
|
Adolescent | 5 | 2018 | 6195 | 0.200 |
Why?
|
Oligonucleotide Array Sequence Analysis | 3 | 2014 | 298 | 0.190 |
Why?
|
Glycoproteins | 5 | 2006 | 187 | 0.190 |
Why?
|
In Vitro Techniques | 3 | 2013 | 487 | 0.190 |
Why?
|
Carcinoma, Squamous Cell | 4 | 2011 | 255 | 0.180 |
Why?
|
5-alpha Reductase Inhibitors | 1 | 2001 | 6 | 0.180 |
Why?
|
Dihydrotestosterone | 1 | 2001 | 19 | 0.180 |
Why?
|
Response Elements | 1 | 2001 | 44 | 0.180 |
Why?
|
Antigens, Ly | 1 | 2001 | 42 | 0.180 |
Why?
|
Prostate | 1 | 2001 | 81 | 0.170 |
Why?
|
Testosterone | 1 | 2001 | 119 | 0.170 |
Why?
|
Receptors, Cytoplasmic and Nuclear | 1 | 2001 | 147 | 0.160 |
Why?
|
Hyperplasia | 2 | 2018 | 87 | 0.160 |
Why?
|
Microsatellite Instability | 1 | 2019 | 3 | 0.160 |
Why?
|
Heredity | 1 | 2019 | 6 | 0.160 |
Why?
|
Prognosis | 3 | 2013 | 1727 | 0.160 |
Why?
|
Genetic Counseling | 1 | 2019 | 16 | 0.150 |
Why?
|
MutS Homolog 2 Protein | 1 | 2019 | 28 | 0.150 |
Why?
|
Tail | 2 | 2016 | 6 | 0.150 |
Why?
|
Pedigree | 1 | 2019 | 193 | 0.150 |
Why?
|
Point Mutation | 1 | 2019 | 166 | 0.150 |
Why?
|
Base Sequence | 3 | 2015 | 1335 | 0.150 |
Why?
|
Liver | 2 | 2001 | 846 | 0.150 |
Why?
|
Platelet Endothelial Cell Adhesion Molecule-1 | 2 | 2010 | 16 | 0.150 |
Why?
|
RNA, Messenger | 6 | 2006 | 1534 | 0.150 |
Why?
|
Fibrosarcoma | 1 | 1998 | 13 | 0.140 |
Why?
|
Antigens, CD34 | 2 | 2010 | 56 | 0.140 |
Why?
|
Sunlight | 1 | 2018 | 30 | 0.140 |
Why?
|
Hydrogen Peroxide | 1 | 1998 | 78 | 0.140 |
Why?
|
High-Throughput Nucleotide Sequencing | 2 | 2017 | 311 | 0.140 |
Why?
|
Skin Abnormalities | 1 | 2017 | 8 | 0.140 |
Why?
|
Nails, Malformed | 1 | 2017 | 6 | 0.140 |
Why?
|
Gene Expression Profiling | 3 | 2017 | 769 | 0.140 |
Why?
|
Molecular Sequence Data | 3 | 2015 | 1997 | 0.140 |
Why?
|
Papillomaviridae | 2 | 2014 | 59 | 0.140 |
Why?
|
Biopsy | 1 | 2019 | 431 | 0.140 |
Why?
|
Catalase | 1 | 1996 | 24 | 0.130 |
Why?
|
gp100 Melanoma Antigen | 1 | 2016 | 5 | 0.130 |
Why?
|
Cell Transformation, Neoplastic | 1 | 1998 | 207 | 0.130 |
Why?
|
Biological Ontologies | 1 | 2016 | 1 | 0.130 |
Why?
|
Carcinoma, Basal Cell | 2 | 2025 | 67 | 0.130 |
Why?
|
Dysplastic Nevus Syndrome | 1 | 2016 | 2 | 0.130 |
Why?
|
Cluster Analysis | 1 | 2017 | 258 | 0.130 |
Why?
|
Hyperpigmentation | 1 | 2016 | 6 | 0.130 |
Why?
|
GTP-Binding Protein alpha Subunits, Gi-Go | 1 | 2016 | 15 | 0.130 |
Why?
|
Dermis | 2 | 2016 | 18 | 0.130 |
Why?
|
Fibroblasts | 1 | 1998 | 392 | 0.120 |
Why?
|
Area Under Curve | 1 | 2016 | 146 | 0.120 |
Why?
|
Alopecia Areata | 1 | 2015 | 10 | 0.120 |
Why?
|
Mice, Inbred C57BL | 7 | 2017 | 3389 | 0.120 |
Why?
|
Clobetasol | 1 | 2015 | 6 | 0.120 |
Why?
|
Administration, Cutaneous | 1 | 2015 | 31 | 0.120 |
Why?
|
ROC Curve | 1 | 2016 | 279 | 0.120 |
Why?
|
Keratoderma, Palmoplantar | 1 | 2015 | 4 | 0.120 |
Why?
|
Desmoplakins | 1 | 2015 | 9 | 0.120 |
Why?
|
Dermatologic Agents | 1 | 2015 | 21 | 0.120 |
Why?
|
Hair Diseases | 1 | 2015 | 6 | 0.120 |
Why?
|
Infliximab | 1 | 2015 | 49 | 0.120 |
Why?
|
Papilloma | 1 | 2014 | 12 | 0.120 |
Why?
|
Genetic Predisposition to Disease | 1 | 2019 | 716 | 0.120 |
Why?
|
Microscopy, Fluorescence | 2 | 2014 | 400 | 0.120 |
Why?
|
Blotting, Northern | 2 | 2009 | 150 | 0.110 |
Why?
|
Acyl-CoA Oxidase | 3 | 2001 | 7 | 0.110 |
Why?
|
Rituximab | 1 | 2015 | 84 | 0.110 |
Why?
|
Mutation, Missense | 1 | 2016 | 187 | 0.110 |
Why?
|
Sequence Homology, Nucleic Acid | 1 | 2014 | 113 | 0.110 |
Why?
|
Sebaceous Glands | 2 | 2017 | 6 | 0.110 |
Why?
|
Rats | 5 | 2009 | 1980 | 0.110 |
Why?
|
Infant | 3 | 2010 | 1623 | 0.110 |
Why?
|
Mice, Congenic | 1 | 2014 | 22 | 0.110 |
Why?
|
Pigmentation | 1 | 2014 | 25 | 0.110 |
Why?
|
Neoplasm Transplantation | 1 | 2014 | 165 | 0.110 |
Why?
|
Melanoma, Experimental | 1 | 2014 | 42 | 0.110 |
Why?
|
Apoptosis | 2 | 2003 | 1066 | 0.110 |
Why?
|
Drug Therapy, Combination | 1 | 2015 | 463 | 0.110 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 2 | 2013 | 545 | 0.110 |
Why?
|
Glucocorticoids | 1 | 2015 | 188 | 0.100 |
Why?
|
DNA, Neoplasm | 1 | 2013 | 58 | 0.100 |
Why?
|
Cardiomyopathies | 1 | 2015 | 123 | 0.100 |
Why?
|
Chromosome Aberrations | 1 | 2013 | 68 | 0.100 |
Why?
|
Transcription Factors | 1 | 2001 | 1508 | 0.100 |
Why?
|
Epigenomics | 1 | 2013 | 62 | 0.100 |
Why?
|
In Situ Hybridization, Fluorescence | 1 | 2013 | 169 | 0.100 |
Why?
|
Gene Silencing | 1 | 2014 | 392 | 0.100 |
Why?
|
Lymphangioma | 1 | 2011 | 3 | 0.090 |
Why?
|
Condylomata Acuminata | 1 | 2011 | 9 | 0.090 |
Why?
|
T-Lymphocytes | 2 | 2014 | 1005 | 0.090 |
Why?
|
Aminoquinolines | 1 | 2011 | 16 | 0.090 |
Why?
|
Molecular Diagnostic Techniques | 1 | 2011 | 32 | 0.090 |
Why?
|
Cell Proliferation | 4 | 2013 | 981 | 0.090 |
Why?
|
Lichen Sclerosus et Atrophicus | 1 | 2011 | 16 | 0.090 |
Why?
|
Granuloma, Pyogenic | 1 | 2010 | 3 | 0.090 |
Why?
|
Nevus, Epithelioid and Spindle Cell | 1 | 2010 | 4 | 0.080 |
Why?
|
Immunophenotyping | 1 | 2010 | 193 | 0.080 |
Why?
|
Neoplasm Staging | 2 | 2008 | 487 | 0.080 |
Why?
|
RNA, Small Interfering | 2 | 2014 | 898 | 0.080 |
Why?
|
Calreticulin | 1 | 2009 | 4 | 0.080 |
Why?
|
Cytoplasm | 1 | 2010 | 277 | 0.080 |
Why?
|
Epidermolysis Bullosa Dystrophica | 1 | 2009 | 15 | 0.080 |
Why?
|
Retrospective Studies | 3 | 2018 | 6545 | 0.080 |
Why?
|
Genes, Recessive | 1 | 2009 | 52 | 0.080 |
Why?
|
Adenocarcinoma, Sebaceous | 1 | 2008 | 2 | 0.080 |
Why?
|
Sebaceous Gland Neoplasms | 1 | 2008 | 10 | 0.080 |
Why?
|
Cell Line | 2 | 2011 | 2039 | 0.080 |
Why?
|
Neoplasms, Second Primary | 2 | 2011 | 47 | 0.080 |
Why?
|
Mice, Knockout | 3 | 2017 | 2105 | 0.080 |
Why?
|
Mice, Nude | 3 | 2014 | 271 | 0.080 |
Why?
|
Lung | 1 | 2014 | 939 | 0.080 |
Why?
|
Nerve Sheath Neoplasms | 1 | 2008 | 5 | 0.070 |
Why?
|
Vascular Endothelial Growth Factor Receptor-3 | 1 | 2008 | 21 | 0.070 |
Why?
|
Neurilemmoma | 1 | 2008 | 12 | 0.070 |
Why?
|
Cystadenocarcinoma, Serous | 1 | 2008 | 13 | 0.070 |
Why?
|
Inflammation | 2 | 2006 | 1142 | 0.070 |
Why?
|
Stromal Cells | 1 | 2008 | 67 | 0.070 |
Why?
|
Neoplastic Stem Cells | 1 | 2009 | 203 | 0.070 |
Why?
|
Predictive Value of Tests | 1 | 2010 | 1078 | 0.070 |
Why?
|
Lymphatic Vessels | 1 | 2008 | 32 | 0.070 |
Why?
|
Cells, Cultured | 3 | 2013 | 2155 | 0.070 |
Why?
|
Scalp | 1 | 2007 | 29 | 0.070 |
Why?
|
Cell Nucleus | 1 | 2010 | 623 | 0.070 |
Why?
|
Antibodies, Monoclonal | 2 | 2008 | 866 | 0.070 |
Why?
|
Ovarian Neoplasms | 1 | 2008 | 145 | 0.070 |
Why?
|
Lymphedema | 1 | 2006 | 7 | 0.070 |
Why?
|
Fluorodeoxyglucose F18 | 1 | 2007 | 95 | 0.060 |
Why?
|
Thyroid Neoplasms | 1 | 2007 | 73 | 0.060 |
Why?
|
Dermatitis | 1 | 2006 | 28 | 0.060 |
Why?
|
Endothelial Cells | 2 | 2004 | 185 | 0.060 |
Why?
|
Positron-Emission Tomography | 1 | 2007 | 208 | 0.060 |
Why?
|
Vascular Endothelial Growth Factor D | 1 | 2005 | 2 | 0.060 |
Why?
|
Antineoplastic Agents | 1 | 2011 | 661 | 0.060 |
Why?
|
Prostatic Neoplasms | 1 | 2009 | 397 | 0.060 |
Why?
|
Head and Neck Neoplasms | 1 | 2007 | 167 | 0.060 |
Why?
|
Neoplasms, Germ Cell and Embryonal | 1 | 2005 | 9 | 0.060 |
Why?
|
Organ Size | 2 | 2006 | 171 | 0.060 |
Why?
|
Gene Expression | 3 | 2013 | 838 | 0.060 |
Why?
|
Mucins | 1 | 2005 | 26 | 0.060 |
Why?
|
Scleral Diseases | 1 | 2004 | 1 | 0.060 |
Why?
|
Orbital Neoplasms | 1 | 2004 | 6 | 0.060 |
Why?
|
Fluorescent Antibody Technique | 1 | 2004 | 233 | 0.060 |
Why?
|
Eye Neoplasms | 1 | 2004 | 17 | 0.050 |
Why?
|
Thrombospondins | 1 | 2003 | 6 | 0.050 |
Why?
|
Thrombocytopenia | 1 | 2004 | 53 | 0.050 |
Why?
|
Endothelial Growth Factors | 1 | 2003 | 21 | 0.050 |
Why?
|
Blood Vessels | 1 | 2003 | 62 | 0.050 |
Why?
|
Mice, Inbred Strains | 2 | 2016 | 189 | 0.050 |
Why?
|
Hematopoietic Stem Cell Transplantation | 1 | 2025 | 350 | 0.050 |
Why?
|
Tomography, X-Ray Computed | 2 | 2007 | 1589 | 0.050 |
Why?
|
Survival Analysis | 1 | 2003 | 578 | 0.050 |
Why?
|
Blotting, Western | 2 | 2005 | 610 | 0.050 |
Why?
|
Peroxisome Proliferators | 1 | 2001 | 1 | 0.040 |
Why?
|
3-Oxo-5-alpha-Steroid 4-Dehydrogenase | 1 | 2001 | 2 | 0.040 |
Why?
|
Finasteride | 1 | 2001 | 5 | 0.040 |
Why?
|
Orchiectomy | 1 | 2001 | 31 | 0.040 |
Why?
|
Drug Synergism | 1 | 2001 | 142 | 0.040 |
Why?
|
Luciferases | 2 | 2006 | 109 | 0.040 |
Why?
|
Transfection | 2 | 2005 | 691 | 0.040 |
Why?
|
Testis | 1 | 2001 | 141 | 0.040 |
Why?
|
Gene Deletion | 1 | 2001 | 307 | 0.040 |
Why?
|
Recombinant Proteins | 2 | 2003 | 700 | 0.040 |
Why?
|
Rats, Sprague-Dawley | 1 | 2001 | 622 | 0.040 |
Why?
|
Postoperative Complications | 1 | 2006 | 1284 | 0.040 |
Why?
|
Cell Differentiation | 1 | 2004 | 1348 | 0.040 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2001 | 863 | 0.040 |
Why?
|
Erucic Acids | 1 | 1998 | 1 | 0.040 |
Why?
|
In Situ Nick-End Labeling | 1 | 1998 | 47 | 0.040 |
Why?
|
Colony-Forming Units Assay | 1 | 1998 | 27 | 0.040 |
Why?
|
Fatty Acids, Monounsaturated | 1 | 1998 | 17 | 0.040 |
Why?
|
Linoleic Acid | 1 | 1998 | 19 | 0.040 |
Why?
|
Vibrissae | 1 | 2017 | 7 | 0.030 |
Why?
|
DNA Primers | 1 | 1998 | 293 | 0.030 |
Why?
|
Ranidae | 1 | 1996 | 3 | 0.030 |
Why?
|
Mice, Transgenic | 2 | 2006 | 1273 | 0.030 |
Why?
|
Elastin | 1 | 2016 | 10 | 0.030 |
Why?
|
Elasticity | 1 | 2016 | 43 | 0.030 |
Why?
|
False Negative Reactions | 1 | 2016 | 40 | 0.030 |
Why?
|
False Positive Reactions | 1 | 2016 | 78 | 0.030 |
Why?
|
Gene Expression Regulation, Enzymologic | 1 | 1996 | 131 | 0.030 |
Why?
|
Tissue Distribution | 1 | 1996 | 293 | 0.030 |
Why?
|
Xenograft Model Antitumor Assays | 2 | 2009 | 189 | 0.030 |
Why?
|
Collagen | 1 | 2016 | 127 | 0.030 |
Why?
|
Publications | 1 | 2016 | 29 | 0.030 |
Why?
|
Species Specificity | 1 | 2016 | 336 | 0.030 |
Why?
|
Ethylnitrosourea | 1 | 2016 | 11 | 0.030 |
Why?
|
Data Mining | 1 | 2016 | 38 | 0.030 |
Why?
|
Cloning, Molecular | 1 | 1996 | 383 | 0.030 |
Why?
|
Microscopy, Confocal | 1 | 2016 | 234 | 0.030 |
Why?
|
Random Allocation | 1 | 2016 | 198 | 0.030 |
Why?
|
Biopsy, Needle | 1 | 2016 | 137 | 0.030 |
Why?
|
DNA-Activated Protein Kinase | 1 | 2014 | 12 | 0.030 |
Why?
|
Frameshift Mutation | 1 | 2015 | 29 | 0.030 |
Why?
|
Genetic Linkage | 1 | 2015 | 95 | 0.030 |
Why?
|
Cardiomyopathy, Dilated | 1 | 2015 | 36 | 0.030 |
Why?
|
3-Hydroxyacyl CoA Dehydrogenases | 1 | 1994 | 3 | 0.030 |
Why?
|
Enoyl-CoA Hydratase | 1 | 1994 | 2 | 0.030 |
Why?
|
Alleles | 1 | 2016 | 449 | 0.030 |
Why?
|
Forkhead Transcription Factors | 1 | 2014 | 129 | 0.030 |
Why?
|
Promoter Regions, Genetic | 1 | 1996 | 672 | 0.030 |
Why?
|
DNA, Viral | 1 | 2014 | 232 | 0.030 |
Why?
|
Genes, Reporter | 1 | 1994 | 256 | 0.030 |
Why?
|
Amino Acid Sequence | 1 | 1996 | 1595 | 0.030 |
Why?
|
Mice, Inbred NOD | 1 | 2014 | 521 | 0.030 |
Why?
|
Gene Regulatory Networks | 1 | 2014 | 158 | 0.030 |
Why?
|
Sequence Analysis, DNA | 1 | 2015 | 413 | 0.030 |
Why?
|
Interleukin-2 Receptor alpha Subunit | 1 | 2013 | 25 | 0.030 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2016 | 495 | 0.030 |
Why?
|
Time Factors | 1 | 2001 | 3749 | 0.030 |
Why?
|
Genome | 1 | 2015 | 275 | 0.030 |
Why?
|
Coculture Techniques | 1 | 2013 | 97 | 0.030 |
Why?
|
Internet | 1 | 2016 | 464 | 0.020 |
Why?
|
T-Lymphocytes, Cytotoxic | 1 | 2013 | 174 | 0.020 |
Why?
|
Epitopes, T-Lymphocyte | 1 | 2013 | 181 | 0.020 |
Why?
|
B-Lymphocytes | 1 | 2014 | 570 | 0.020 |
Why?
|
Radiotherapy | 1 | 2011 | 64 | 0.020 |
Why?
|
Hysterectomy | 1 | 2011 | 67 | 0.020 |
Why?
|
Receptors, Antigen, T-Cell | 1 | 2013 | 287 | 0.020 |
Why?
|
Flow Cytometry | 1 | 2013 | 670 | 0.020 |
Why?
|
T-Lymphocytes, Regulatory | 1 | 2013 | 213 | 0.020 |
Why?
|
Uterine Cervical Neoplasms | 1 | 2011 | 140 | 0.020 |
Why?
|
Lymph Node Excision | 1 | 2010 | 42 | 0.020 |
Why?
|
Nuclear Proteins | 1 | 2014 | 775 | 0.020 |
Why?
|
Papillomavirus Infections | 1 | 2011 | 128 | 0.020 |
Why?
|
Hypertelorism | 1 | 2009 | 1 | 0.020 |
Why?
|
Retrognathia | 1 | 2009 | 1 | 0.020 |
Why?
|
Cross-Sectional Studies | 1 | 2016 | 2558 | 0.020 |
Why?
|
Collagen Type VII | 1 | 2009 | 5 | 0.020 |
Why?
|
Palate | 1 | 2009 | 8 | 0.020 |
Why?
|
Keratinocytes | 1 | 2009 | 65 | 0.020 |
Why?
|
Abnormalities, Multiple | 1 | 2009 | 54 | 0.020 |
Why?
|
Cytokines | 1 | 2013 | 934 | 0.020 |
Why?
|
Microscopy, Electron | 1 | 2009 | 250 | 0.020 |
Why?
|
Neurofibroma | 1 | 2008 | 2 | 0.020 |
Why?
|
Antibodies, Monoclonal, Murine-Derived | 1 | 2008 | 58 | 0.020 |
Why?
|
Schwann Cells | 1 | 2008 | 8 | 0.020 |
Why?
|
Adenoma | 1 | 2008 | 68 | 0.020 |
Why?
|
S100 Proteins | 1 | 2008 | 19 | 0.020 |
Why?
|
Tissue Array Analysis | 1 | 2008 | 35 | 0.020 |
Why?
|
DNA-Binding Proteins | 1 | 2014 | 1184 | 0.020 |
Why?
|
Down-Regulation | 1 | 2009 | 318 | 0.020 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2013 | 671 | 0.020 |
Why?
|
Mice, Inbred BALB C | 2 | 2003 | 893 | 0.020 |
Why?
|
Lung Diseases | 1 | 2009 | 175 | 0.020 |
Why?
|
Protein Structure, Tertiary | 1 | 2009 | 670 | 0.020 |
Why?
|
Immunocompetence | 1 | 2006 | 21 | 0.020 |
Why?
|
Mice, Hairless | 1 | 2006 | 18 | 0.020 |
Why?
|
Lymphoscintigraphy | 1 | 2006 | 6 | 0.020 |
Why?
|
Cohort Studies | 1 | 2013 | 2549 | 0.020 |
Why?
|
Lymphocyte Subsets | 1 | 2006 | 37 | 0.020 |
Why?
|
Microspheres | 1 | 2006 | 56 | 0.020 |
Why?
|
Granulocytes | 1 | 2006 | 71 | 0.020 |
Why?
|
Complement Activation | 1 | 2006 | 50 | 0.020 |
Why?
|
Radiopharmaceuticals | 1 | 2007 | 186 | 0.020 |
Why?
|
Fibrosis | 1 | 2006 | 159 | 0.020 |
Why?
|
Membrane Transport Proteins | 1 | 2006 | 134 | 0.020 |
Why?
|
Case-Control Studies | 1 | 2008 | 1115 | 0.020 |
Why?
|
Granulosa Cell Tumor | 1 | 2005 | 5 | 0.010 |
Why?
|
Granulosa Cells | 1 | 2005 | 16 | 0.010 |
Why?
|
Cell Lineage | 1 | 2006 | 268 | 0.010 |
Why?
|
Wound Healing | 1 | 2006 | 189 | 0.010 |
Why?
|
Spleen | 1 | 2006 | 482 | 0.010 |
Why?
|
Epithelium | 1 | 2005 | 95 | 0.010 |
Why?
|
Infant, Newborn | 1 | 2009 | 1348 | 0.010 |
Why?
|
Ovary | 1 | 2005 | 99 | 0.010 |
Why?
|
Oxidative Stress | 1 | 2006 | 294 | 0.010 |
Why?
|
Orbit Evisceration | 1 | 2004 | 2 | 0.010 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2005 | 455 | 0.010 |
Why?
|
Recombinant Fusion Proteins | 1 | 2005 | 495 | 0.010 |
Why?
|
Biomarkers | 1 | 2008 | 1388 | 0.010 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2003 | 205 | 0.010 |
Why?
|
Transcription, Genetic | 1 | 2006 | 875 | 0.010 |
Why?
|
Kidney | 1 | 2003 | 444 | 0.010 |
Why?
|
Mutation | 1 | 2009 | 2598 | 0.010 |
Why?
|
Disease Progression | 1 | 2005 | 1159 | 0.010 |
Why?
|
Treatment Outcome | 1 | 2010 | 5596 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 1 | 2004 | 2150 | 0.010 |
Why?
|
Clofibric Acid | 1 | 1994 | 1 | 0.010 |
Why?
|
Nafenopin | 1 | 1994 | 1 | 0.010 |
Why?
|
Fibric Acids | 1 | 1994 | 2 | 0.010 |
Why?
|
Diethylhexyl Phthalate | 1 | 1994 | 4 | 0.010 |
Why?
|
Mice, Inbred DBA | 1 | 1994 | 84 | 0.010 |
Why?
|
Pyrimidines | 1 | 1994 | 135 | 0.010 |
Why?
|